
Benjamin A. Schiffman
Examiner (ID: 15490, Phone: (571)270-7626 , Office: P/1742 )
| Most Active Art Unit | 1742 |
| Art Unit(s) | 1791, 4191, 1742 |
| Total Applications | 1223 |
| Issued Applications | 792 |
| Pending Applications | 80 |
| Abandoned Applications | 367 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18595995
[patent_doc_number] => 20230270786
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
[patent_app_type] => utility
[patent_app_number] => 18/175347
[patent_app_country] => US
[patent_app_date] => 2023-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53743
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175347
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/175347 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | Feb 26, 2023 | Pending |
Array
(
[id] => 19173778
[patent_doc_number] => 20240159752
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => METHODS FOR COLORECTAL CANCER DIAGNOSIS AND PROGNOSIS
[patent_app_type] => utility
[patent_app_number] => 18/171399
[patent_app_country] => US
[patent_app_date] => 2023-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14659
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 359
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18171399
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/171399 | METHODS FOR COLORECTAL CANCER DIAGNOSIS AND PROGNOSIS | Feb 19, 2023 | Pending |
Array
(
[id] => 18657728
[patent_doc_number] => 20230303678
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP
[patent_app_type] => utility
[patent_app_number] => 18/158767
[patent_app_country] => US
[patent_app_date] => 2023-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34896
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158767
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/158767 | METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP | Jan 23, 2023 | Pending |
Array
(
[id] => 19551072
[patent_doc_number] => 12134771
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-05
[patent_title] => Fusion protein and use thereof in base editing
[patent_app_type] => utility
[patent_app_number] => 18/150778
[patent_app_country] => US
[patent_app_date] => 2023-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 16
[patent_no_of_words] => 15334
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18150778
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/150778 | Fusion protein and use thereof in base editing | Jan 4, 2023 | Issued |
Array
(
[id] => 18307058
[patent_doc_number] => 20230110958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/887565
[patent_app_country] => US
[patent_app_date] => 2022-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17887565
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Aug 14, 2022 | Pending |
Array
(
[id] => 18895204
[patent_doc_number] => 20240010689
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => CHIMERIC KLEBICINS
[patent_app_type] => utility
[patent_app_number] => 17/811492
[patent_app_country] => US
[patent_app_date] => 2022-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15758
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811492
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811492 | CHIMERIC KLEBICINS | Jul 7, 2022 | Pending |
Array
(
[id] => 18077377
[patent_doc_number] => 20220402989
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => IL2-BASED THERAPEUTICS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/806566
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -68
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17806566
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/806566 | IL2-based therapeutics and methods of use thereof | Jun 12, 2022 | Issued |
Array
(
[id] => 19969701
[patent_doc_number] => 12338293
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-24
[patent_title] => UPAR antibodies and fusion proteins with the same
[patent_app_type] => utility
[patent_app_number] => 17/702329
[patent_app_country] => US
[patent_app_date] => 2022-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 24
[patent_no_of_words] => 31861
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 263
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17702329
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/702329 | UPAR antibodies and fusion proteins with the same | Mar 22, 2022 | Issued |
Array
(
[id] => 18210010
[patent_doc_number] => 20230056271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERS
[patent_app_type] => utility
[patent_app_number] => 17/654209
[patent_app_country] => US
[patent_app_date] => 2022-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 91790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17654209
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/654209 | DARPin based multi-specific t-cell engagers | Mar 8, 2022 | Issued |
Array
(
[id] => 19172542
[patent_doc_number] => 20240158516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/548484
[patent_app_country] => US
[patent_app_date] => 2022-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39750
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -93
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18548484
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/548484 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | Mar 2, 2022 | Pending |
Array
(
[id] => 17828415
[patent_doc_number] => 20220265719
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => IMMUNOTHERAPIES
[patent_app_type] => utility
[patent_app_number] => 17/675294
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71481
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675294
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/675294 | IMMUNOTHERAPIES | Feb 17, 2022 | Pending |
Array
(
[id] => 17960042
[patent_doc_number] => 20220340622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => RECOMBINANT HAGFISH PROTEINS AND FIBERS
[patent_app_type] => utility
[patent_app_number] => 17/651020
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13381
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17651020
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/651020 | Recombinant hagfish proteins and fibers | Feb 13, 2022 | Issued |
Array
(
[id] => 20219949
[patent_doc_number] => 20250282880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-11
[patent_title] => ANTIBODY VARIABLE DOMAINS THAT BIND IL-4R
[patent_app_type] => utility
[patent_app_number] => 18/258939
[patent_app_country] => US
[patent_app_date] => 2021-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24408
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258939
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/258939 | ANTIBODY VARIABLE DOMAINS THAT BIND IL-4R | Dec 22, 2021 | Pending |
Array
(
[id] => 19738351
[patent_doc_number] => 12215169
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-04
[patent_title] => Anti-complement C1s antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/556061
[patent_app_country] => US
[patent_app_date] => 2021-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 4
[patent_no_of_words] => 64628
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556061
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/556061 | Anti-complement C1s antibodies and uses thereof | Dec 19, 2021 | Issued |
Array
(
[id] => 19667556
[patent_doc_number] => 12180284
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-31
[patent_title] => Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector
[patent_app_type] => utility
[patent_app_number] => 17/553333
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 28
[patent_no_of_words] => 45337
[patent_no_of_claims] => 41
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553333
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/553333 | Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector | Dec 15, 2021 | Issued |
Array
(
[id] => 17704641
[patent_doc_number] => 20220204647
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/548135
[patent_app_country] => US
[patent_app_date] => 2021-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49815
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548135
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/548135 | Anti-complement C1s antibodies and uses thereof | Dec 9, 2021 | Issued |
Array
(
[id] => 18971963
[patent_doc_number] => 20240052055
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => GPC3 ANTIBODY AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/266393
[patent_app_country] => US
[patent_app_date] => 2021-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14489
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266393
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/266393 | GPC3 ANTIBODY AND APPLICATION THEREOF | Dec 8, 2021 | Pending |
Array
(
[id] => 18923000
[patent_doc_number] => 20240026004
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => ANTI-PD-L1/TGF-ss BIFUNCTIONAL ANTIBODY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/039733
[patent_app_country] => US
[patent_app_date] => 2021-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039733
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/039733 | ANTI-PD-L1/TGF-ss BIFUNCTIONAL ANTIBODY AND USE THEREOF | Nov 30, 2021 | Pending |
Array
(
[id] => 18901446
[patent_doc_number] => 20240016931
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/039604
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25428
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039604
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/039604 | ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | Nov 21, 2021 | Pending |
Array
(
[id] => 18861964
[patent_doc_number] => 20230416400
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => CHIMERIC ANTI-HUMAN BRAF V600E ANTIBODIES AND METHODS FOR MAKING AND USING THEM
[patent_app_type] => utility
[patent_app_number] => 18/037243
[patent_app_country] => US
[patent_app_date] => 2021-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12060
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18037243
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/037243 | CHIMERIC ANTI-HUMAN BRAF V600E ANTIBODIES AND METHODS FOR MAKING AND USING THEM | Nov 14, 2021 | Pending |